Clincosm LogoSign in Get a demo

Diffuse Large B-cell Lymphoma

Showing 1 - 25 of 231
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Mitoxantrone hydrochloride liposome injection
  • +4 more
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Aug 15, 2023

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

Completed
  • Diffuse Large B-cell Lymphoma
    • East Hanover, New Jersey
      Novartis
    Jun 16, 2023

    DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • maplirpacept (PF-07901801)
    • +2 more
    • (no location specified)
    May 30, 2023

    Tafasitamab in Combination With Lenalidomide in Patients withR/R

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Tafasitamab Injection
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    May 31, 2023

    DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • Mitoxantrone Hydrochloride Liposome Injection
    • Jinan, Shandong, China
      Affiliated Cancer Hospital of Shandong First Medical University
    May 16, 2023

    DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Apr 10, 2023

    Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • (no location specified)
    Mar 23, 2023

    Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • (no location specified)
    Mar 9, 2023

    Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Metabolically Armed CD19 CAR-T cells
    • Hefei, Anhui, China
      Anhui Provincial Hospital
    Feb 9, 2023

    DLBCL Trial in Worldwide (Polatuzumab Vedotin, Rituximab, Gemcitabine)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Polatuzumab Vedotin
    • +3 more
    • Hollywood, Florida
    • +89 more
    Jan 31, 2023

    DLBCL Trial in Worldwide (Epcoritamab, Cyclophosphamide, Rituximab)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Birmingham, Alabama
    • +376 more
    Jan 30, 2023

    Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)

    Terminated
    • Diffuse Large B-cell Lymphoma
    • Tampa, Florida
    • +1 more
    Jan 27, 2023

    CNS Lymphoma, DLBCL Trial in United States (Lenalidomide, Methotrexate, Nivolumab)

    Recruiting
    • Central Nervous System Lymphoma
    • Diffuse Large B-Cell Lymphoma
    • Los Angeles, California
    • +42 more
    Jan 26, 2023

    Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia Trial in United States (TTI-622, Azacitidine, Venetoclax)

    Recruiting
    • Lymphoma
    • +3 more
    • Los Angeles, California
    • +36 more
    Jan 23, 2023

    DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • San Juan, Puerto Rico
      Auxilio Mutuo Cancer Center
    Jan 19, 2023

    Chidamide in Recurrent and Refractory Diffuse Large b

    Enrolling by invitation
    • Diffuse Large B-cell Lymphoma
    • Suzhou, Jiangsu, China
      Second Affiliated Hospital of Soochow University
    Jan 9, 2023

    Diffuse Large B-cell Lymphoma Trial in Switzerland (Acalabrutinib)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Bergamo, Italy
    • +16 more
    Jan 17, 2023

    Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States

    Active, not recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +14 more
    • Cholecalciferol
    • Laboratory Biomarker Analysis
    • Scottsdale, Arizona
    • +4 more
    Jan 16, 2023

    Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)

    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • +11 more
    • Zilovertamab vedotin
    • Duarte, California
    • +13 more
    Jan 12, 2023

    DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +6 more
    • Axicabtagene Ciloleucel
    • +10 more
    • (no location specified)
    Jan 13, 2023

    DLBCL Trial in Japan (MT-2111)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Nagoya-shi, Aichi, Japan
    • +3 more
    Jan 12, 2023